ENG
Liraglutide Market Size, Share, Growth Trends, Industry Analysis, Key Players, Investment Opportunities and Forecast (2025-2032)
Liraglutide Market size was valued at nearly USD 4 Bn in 2024, and the total Global Liraglutide Market revenue is expected to grow at a CAGR of 9.3% from 2025 to 2032, reaching nearly USD 8.91 Bn by 2032.
Format : PDF | Report ID : SMR_2691
Liraglutide Market Overview
Liraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analogue and an effective treatment for patients with metabolic diseases including type 2 diabetes mellitus (T2DM) and obesity. Liraglutide decreases haemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients when prescribes as monotherapy or in combination with one or more antidiabetic drugs.
The major factors attributing to the boom of the market are an increase in weight problems among humans and a rising prevalence price of type-2 diabetes along with coronary heart illnesses. People with greater fats in their bodies are especially in likelihood to be suffering from diabetes. According to the United Nations estimates published in March 2022, multiple billion people had been overweight, such as 650 Mn adults, 340 Mn adolescents, and 39 Mn children, and the numbers are likely to rise. The World Health Organization predicted that by means of 2025, 167 Mn humans are likely to become obese. This fuels the growth in the liraglutide market.
- In 2024, Novo Nordisk's parent company, Novo Holdings A/S, received Catalent for $16.5 billion, improving manufacturing skills for liraglutide-based pills like Victoza and Saxenda.
- Hikma Pharmaceuticals released the first generic version of liraglutide in the U.S. Market in December 2024, to get entry to low priced remedy options.
Biocon Limited partnered with Juno Pharmaceuticals in October 2023 to commercialize liraglutide in Canada, aiming to improve the availability of innovative treatments for type 2 diabetes and weight problems via inexpensive biosimilars. These strategic moves replicate the enterprise's attention on increasing access to GLP-1 treatment options and enhancing production talents to satisfy the rising international call.
To get more Insights: Request Free Sample Report
Liraglutide Market Dynamics
Telehealth adoption of liraglutide to boost the liraglutide market
Adoption of Liraglutides telecommunications health is accelerating owing to its ability and accessibility. For example, Hims & Hers offers a generic version of Liraglutide at $ 299/month, which is much lower than a cost of $ 1,899/month new GLP-1 medicines such as semaglutide and tirzepatide. This cost -effectiveness makes Liraglutide an attractive alternative for patients receiving weight management solutions. The Telehealth model increases the patient's reach by providing distance consultation and home delivery services, and serving individuals in unqualified areas.
Potential side effects to restrain the liraglutide market
Liraglutide's marketplace faces difficult conditions because of its gastrointestinal (GI) side effects. In real-global, 92.3% of Indian youngsters use the liraglutide, suggested GI damaging outcomes, including nausea (71.7%), vomiting (41%), and reduced appetite (69.2%). Additionally, FDA analysed that liraglutide had a considerably danger of pancreatitis compared to distinct GLP-1 receptor agonists, with a reporting odds ratio of 32.67. These component outcomes contribute to high discontinuation rates.
Integration of digital health services to create opportunities in the liraglutide market
The integration of digital fitness services, which include mobile applications, wearable gadgets, and remote monitoring gear, is enhancing patient engagement, adherence, and real-time information series in diabetes and weight problems control. These technologies allow customized remedy modifications, improving patient effects and facilitating more efficient disorder control. The mixture of GLP-1 capsules like liraglutide with digital fitness solutions is a large development inside the enterprise, providing a comprehensive approach to weight reduction and persistent disease control.
Liraglutide Market segment analysis
Based on brand, the liraglutide market is segmented into Victoza, Saxenda and generic segments. Victoza holds the biggest market percent, accounting for approximately 60% of the worldwide liraglutide market in 2024. This dominance is attributed because of its presence inside the marketplace and its primary indication for type 2 diabetes control, which has a broader affected person base in assessment to weight problems treatment.
Based on Dosage form, the liraglutide market is segmented into injectables and oral formulations. The injectable section dominates the liraglutide marketplace, preserving over highest percentage in 2024. This desire is due to the higher bioavailability and set up scientific efficacy of injectable formulations in dealing with type 2 diabetes and weight problems. Injectables provide unique dosing and regular shipping, that are vital for effective treatment outcomes.
Based on distribution channels, the liraglutide market is segmented into hospital pharmacies, retail pharmacies and drug stores, online pharmacies, etc. in 2024, the hospital pharmacies section holds the most significant proportion of the liraglutide marketplace. This dominance is attributed to the centralized nature of health facility settings, in which sufferers get entire care of persistent situations like type 2 diabetes and obesity. Hospital pharmacies are geared up to control complicated remedy regimens and make sure the supply of specialized drugs which incorporates liraglutide.
Based on type of applications, the liraglutide market is segmented into Diabetes treatment, obesity management, etc. The Diabetes treatment application phase holds the most important share of the liraglutide industry. This dominance is attributed to liraglutide's set up efficacy in glycaemic control, its capability to promote weight loss, and its position in reducing cardiovascular risks in diabetic patients. Additionally, the growing global occurrence of type 2 diabetes, driven by means of the use of elements such as obesity, sedentary way of life, and an aging population, has similarly fuelled the decision for liraglutide in diabetes control.
Liraglutide Market regional analysis
North America dominated the liraglutide market
North America leads the global liraglutide market in 2024. This dominance is driven through an excessive incidence of type 2 diabetes and weight problems, strong healthcare infrastructure, and early adoption of superior pharmaceuticals. Also, favourable reimbursement regulations and growing consciousness about diabetes and weight problems control contribute to the excessive call for liraglutide within the region.
Liraglutide Market competitive landscape
Biocon became the number one and first generics business company to accumulate approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for its liraglutide formulations, gVictoza (for diabetes) and gSaxenda (for weight issues). The approval granted in March 2024, and the products was released within the UK in February 2025.
Liraglutide market scope table
|
|
Liraglutide Market Scope |
|||
|
|
Market Size in 2024 |
4 Bn. |
||
|
|
Market Size in 2032 |
8.91 Bn. |
||
|
|
CAGR (2025-2032) |
9.3% |
||
|
|
Historic Data |
2019-2024 |
||
|
|
Base Year |
2024 |
||
|
|
Forecast Period |
2025-2032 |
||
|
|
Segments Analysis |
By Brand Victoza Saxenda Generic |
||
|
|
By Dosage form Injectables Oral formulations |
|||
|
|
By Distribution channels Hospital pharmacies Retail pharmacies and drug stores Online pharmacies Others |
|||
|
|
By End user Diabetes treatment Obesity management Others |
|||
Liraglutide market by Region
North America: United States, Canada, Mexico
Europe: United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe
Asia Pacific (APAC): China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC
Middle East & Africa (MEA): South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Key Players of liraglutide market
North America
- Eli Lilly and Company (US)
- Novo Nordisk Inc. (US)
- Teva Pharmaceuticals (US)
- Sanofi (US)
- Bausch Health Companies (Canada)
- Hikma Pharmaceuticals (US)
- Agmen (US)
Europe
- GlaxoSmithKline plc (UK)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Sandoz International GmbH (Germany)
- Ipsen (France)
- Adalvo (France)
Asia Pacific
- Huadong Medicine (China)
- Benemae Pharmaceutical Corporation (China)
- Biocon Limited (India)
- Glenmark Pharmaceuticals (India)
- Siam Bioscience Co., Ltd (Thailand)
Middle east and Africa
- Aspen Pharmacare (South Africa)
- SEDICO Pharmaceuticals (Egypt)
- Arven Pharmaceuticals (Turkey)
South America
- Hypera Pharma (Brazil)
- EMS (Brazil)
- CFR Pharmaceuticals (Chile)
- Tecnoquímicas (Colombia)
Frequently Asked Questions
The common side effects include gastrointestinal issues such as nausea, vomiting and decreased appetite.
North America holds the largest market share for liraglutide.
Teva Pharmaceuticals launched a generic version of liraglutide in US in 2024.
The segments in the liraglutide market are by brand, by dosage form, by distribution channel and by type of applications.
1. Liraglutide Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Liraglutide Market: Competitive Landscape
2.1. SMR Competition Matrix
2.2. Key Players Benchmarking
2.2.1. Company Name
2.2.2. Service Segment
2.2.3. Type of application Segment
2.2.4. Revenue (2024)
2.2.5. Geographical Presence
2.3. Market Structure
2.3.1. Market Leaders
2.3.2. Market Followers
2.3.3. Emerging Players
2.4. Mergers and Acquisitions Details
3. Liraglutide Market: Dynamics
3.1. Liraglutide Market Trends
3.2. Liraglutide Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
3.5. Regulatory Landscape by Region
3.6. Key Opinion Leader Analysis for the Global Industry
3.7. Analysis of Government Schemes and Initiatives for Industry
4. Liraglutide Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
4.1. Liraglutide Market Size and Forecast, By Brand (2024-2032)
4.1.1. Victoza
4.1.2. Saxenda
4.1.3. Generic
4.2. Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
4.2.1. Injectables
4.2.2. Oral formulations
4.3. Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
4.3.1. Hospital pharmacies
4.3.2. Retail pharmacies and drug stores
4.3.3. Online pharmacies
4.3.4. Others
4.4. Liraglutide Market Size and Forecast, By Type of application (2024-2032)
4.4.1. Diabetes treatment
4.4.2. Obesity management
4.4.3. Others
4.5. Liraglutide Market Size and Forecast, By Region (2024-2032)
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Middle East and Africa
4.5.5. South America
5. North America Liraglutide Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
5.1. North America Liraglutide Market Size and Forecast, By Brand (2024-2032)
5.1.1. Victoza
5.1.2. Saxenda
5.1.3. Generic
5.2. North America Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
5.2.1. Injectables
5.2.2. Oral formulations
5.3. North America Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
5.3.1. Hospital pharmacies
5.3.2. Retail pharmacies and drug stores
5.3.3. Online pharmacies
5.3.4. Others
5.4. North America Liraglutide Market Size and Forecast, By Type of application (2024-2032)
5.4.1. Diabetes treatment
5.4.2. Obesity management
5.4.3. Others
5.5. North America Liraglutide Market Size and Forecast, by Country (2024-2032)
5.5.1. United States
5.5.1.1. United States Liraglutide Market Size and Forecast, By Brand (2024-2032)
5.5.1.1.1. Victoza
5.5.1.1.2. Saxenda
5.5.1.1.3. Generic
5.5.1.2. United States Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
5.5.1.2.1. Injectables
5.5.1.2.2. Oral formulations
5.5.1.3. United States Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
5.5.1.3.1. Hospital pharmacies
5.5.1.3.2. Retail pharmacies and drug stores
5.5.1.3.3. Online pharmacies
5.5.1.3.4. Others
5.5.1.4. United States Liraglutide Market Size and Forecast, By Type of application (2024-2032)
5.5.1.4.1. Diabetes treatment
5.5.1.4.2. Obesity management
5.5.1.4.3. Others
5.5.2. Canada
5.5.2.1. Canada Liraglutide Market Size and Forecast, By Brand (2024-2032)
5.5.2.1.1. Victoza
5.5.2.1.2. Saxenda
5.5.2.1.3. Generic
5.5.2.2. Canada Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
5.5.2.2.1. Injectables
5.5.2.2.2. Oral formulations
5.5.2.3. Canada Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
5.5.2.3.1. Hospital pharmacies
5.5.2.3.2. Retail pharmacies and drug stores
5.5.2.3.3. Online pharmacies
5.5.2.3.4. Others
5.5.2.4. Canada Liraglutide Market Size and Forecast, By Type of application (2024-2032)
5.5.2.4.1. Diabetes treatment
5.5.2.4.2. Obesity management
5.5.2.4.3. Others
5.5.3. Mexico
5.5.3.1. Mexico Liraglutide Market Size and Forecast, By Brand (2024-2032)
5.5.3.1.1. Victoza
5.5.3.1.2. Saxenda
5.5.3.1.3. Generic
5.5.3.2. Mexico Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
5.5.3.2.1. Injectables
5.5.3.2.2. Oral formulations
5.5.3.3. Mexico Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
5.5.3.3.1. Hospital pharmacies
5.5.3.3.2. Retail pharmacies and drug stores
5.5.3.3.3. Online pharmacies
5.5.3.3.4. Others
5.5.3.4. Mexico Liraglutide Market Size and Forecast, By Type of application (2024-2032)
5.5.3.4.1. Diabetes treatment
5.5.3.4.2. Obesity management
5.5.3.4.3. Others
6. Europe Liraglutide Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
6.1. Europe Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.2. Europe Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.3. Europe Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.4. Europe Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5. Europe Liraglutide Market Size and Forecast, by Country (2024-2032)
6.5.1. United Kingdom
6.5.1.1. United Kingdom Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.1.2. United Kingdom Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.1.3. United Kingdom Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.1.4. United Kingdom Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.2. France
6.5.2.1. France Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.2.2. France Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.2.3. France Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.2.4. France Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.3. Germany
6.5.3.1. Germany Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.3.2. Germany Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.3.3. Germany Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.3.4. Germany Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.4. Italy
6.5.4.1. Italy Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.4.2. Italy Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.4.3. Italy Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.4.4. Italy Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.5. Spain
6.5.5.1. Spain Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.5.2. Spain Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.5.3. Spain Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.5.4. Spain Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.6. Sweden
6.5.6.1. Sweden Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.6.2. Sweden Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.6.3. Sweden Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.6.4. Sweden Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.7. Russia
6.5.7.1. Russia Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.7.2. Russia Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.7.3. Russia Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.7.4. Russia Liraglutide Market Size and Forecast, By Type of application (2024-2032)
6.5.8. Rest of Europe
6.5.8.1. Rest of Europe Liraglutide Market Size and Forecast, By Brand (2024-2032)
6.5.8.2. Rest of Europe Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
6.5.8.3. Rest of Europe Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
6.5.8.4. Rest of Europe Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7. Asia Pacific Liraglutide Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
7.1. Asia Pacific Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.2. Asia Pacific Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.3. Asia Pacific Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.4. Asia Pacific Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5. Asia Pacific Liraglutide Market Size and Forecast, by Country (2024-2032)
7.5.1. China
7.5.1.1. China Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.1.2. China Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.1.3. China Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.1.4. China Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.2. S Korea
7.5.2.1. S Korea Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.2.2. S Korea Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.2.3. S Korea Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.2.4. S Korea Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.3. Japan
7.5.3.1. Japan Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.3.2. Japan Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.3.3. Japan Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.3.4. Japan Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.4. India
7.5.4.1. India Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.4.2. India Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.4.3. India Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.4.4. India Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.5. Australia
7.5.5.1. Australia Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.5.2. Australia Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.5.3. Australia Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.5.4. Australia Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.6. Indonesia
7.5.6.1. Indonesia Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.6.2. Indonesia Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.6.3. Indonesia Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.6.4. Indonesia Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.7. Malaysia
7.5.7.1. Malaysia Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.7.2. Malaysia Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.7.3. Malaysia Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.7.4. Malaysia Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.8. Philippines
7.5.8.1. Philippines Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.8.2. Philippines Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.8.3. Philippines Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.8.4. Philippines Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.9. Thailand
7.5.9.1. Thailand Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.9.2. Thailand Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.9.3. Thailand Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.9.4. Thailand Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.10. Vietnam
7.5.10.1. Vietnam Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.10.2. Vietnam Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.10.3. Vietnam Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.10.4. Vietnam Liraglutide Market Size and Forecast, By Type of application (2024-2032)
7.5.11. Rest of Asia Pacific
7.5.11.1. Rest of Asia Pacific Liraglutide Market Size and Forecast, By Brand (2024-2032)
7.5.11.2. Rest of Asia Pacific Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
7.5.11.3. Rest of Asia Pacific Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
7.5.11.4. Rest of Asia Pacific Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8. Middle East and Africa Liraglutide Market Size and Forecast (by Value in USD Million) (2024-2032
8.1. Middle East and Africa Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.2. Middle East and Africa Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.3. Middle East and Africa Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.4. Middle East and Africa Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8.5. Middle East and Africa Liraglutide Market Size and Forecast, by Country (2024-2032)
8.5.1. South Africa
8.5.1.1. South Africa Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.5.1.2. South Africa Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.5.1.3. South Africa Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.5.1.4. South Africa Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8.5.2. GCC
8.5.2.1. GCC Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.5.2.2. GCC Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.5.2.3. GCC Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.5.2.4. GCC Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8.5.3. Egypt
8.5.3.1. Egypt Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.5.3.2. Egypt Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.5.3.3. Egypt Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.5.3.4. Egypt Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8.5.4. Nigeria
8.5.4.1. Nigeria Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.5.4.2. Nigeria Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.5.4.3. Nigeria Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.5.4.4. Nigeria Liraglutide Market Size and Forecast, By Type of application (2024-2032)
8.5.5. Rest of ME&A
8.5.5.1. Rest of ME&A Liraglutide Market Size and Forecast, By Brand (2024-2032)
8.5.5.2. Rest of ME&A Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
8.5.5.3. Rest of ME&A Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
8.5.5.4. Rest of ME&A Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9. South America Liraglutide Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032
9.1. South America Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.2. South America Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.3. South America Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.4. South America Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9.5. South America Liraglutide Market Size and Forecast, by Country (2024-2032)
9.5.1. Brazil
9.5.1.1. Brazil Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.5.1.2. Brazil Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.5.1.3. Brazil Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.5.1.4. Brazil Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9.5.2. Argentina
9.5.2.1. Argentina Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.5.2.2. Argentina Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.5.2.3. Argentina Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.5.2.4. Argentina Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9.5.3. Colombia
9.5.3.1. Colombia Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.5.3.2. Colombia Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.5.3.3. Colombia Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.5.3.4. Colombia Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9.5.4. Chile
9.5.4.1. Chile Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.5.4.2. Chile Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.5.4.3. Chile Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.5.4.4. Chile Liraglutide Market Size and Forecast, By Type of application (2024-2032)
9.5.5. Rest Of South America
9.5.5.1. Rest Of South America Liraglutide Market Size and Forecast, By Brand (2024-2032)
9.5.5.2. Rest Of South America Liraglutide Market Size and Forecast, By Dosage form (2024-2032)
9.5.5.3. Rest Of South America Liraglutide Market Size and Forecast, By Distribution channel (2024-2032)
9.5.5.4. Rest Of South America Liraglutide Market Size and Forecast, By Type of application (2024-2032)
10. Company Profile: Key Players
10.1. Eli Lilly and Company
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Recent Developments
10.2. Novo Nordisk Inc.
10.3. Teva Pharmaceuticals
10.4. Sanofi
10.5. Bausch Health Companies
10.6. Hikma Pharmaceuticals
10.7. Agmen
10.8. GlaxoSmithKline plc
10.9. F. Hoffmann-La Roche Ltd
10.10. Sandoz International GmbH
10.11. Ipsen
10.12. Adalvo
10.13. Huadong Medicine
10.14. Benemae Pharmaceutical Corporation
10.15. Biocon Limited
10.16. Glenmark Pharmaceuticals
10.17. Siam Bioscience Co., Ltd
10.18. Aspen Pharmacare
10.19. SEDICO Pharmaceuticals
10.20. Arven Pharmaceuticals
10.21. Hypera Pharma
10.22. EMS
10.23. CFR Pharmaceuticals
10.24. Tecnoquímicas
11. Key Findings
12. Industry Recommendations
13. Liraglutide Market: Research Methodology
